Hear perspectives from Prof. Ole De Backer and Prof. Nicolas Van Mieghem about the recent DurAVR® THV data and the PARADIGM Trial in this 2-part discussion series. 
 
Part 1 highlights the PARADIGM trial—the first all-comers, head-to-head TAVI trial and the first TAVI trial designed to evaluate post-procedure blood flow patterns using cardiac MRI. With participation from 80 centers across the US, Canada, and Europe, recent FDA IDE approval, and first enrollments already completed in Denmark in October, the PARADIGM Trial is expected to enroll quickly, and the data gathered will be used to support future commercial approval of the DurAVR® valve for patients across all risk categories. 
 
Part 2 focuses on Prof. De Backer’s presentation of 30-day outcomes from 100 small annuli DurAVR® THV patients, providing early insights into clinical performance. DurAVR® THV demonstrated a favorable hemodynamic profile at 30 days, including 97% freedom from moderate or greater patient-prosthesis mismatch (PPM).¹

¹ De Backer O. Oral Presentation at: PCR London Valves; Nov 2025; London, UK.